Uhlig, Till http://orcid.org/0000-0002-6881-9552
Karoliussen, Lars F.
Sexton, Joe
Kvien, Tore K.
Haavardsholm, Espen A.
Perez-Ruiz, Fernando
Hammer, Hilde Berner
Funding for this research was provided by:
Diakonhjemmet
Article History
Received: 11 November 2021
Accepted: 30 March 2022
First Online: 20 April 2022
Declarations
:
: The study was approved by the Norwegian Regional Committee for Medical and Health Research Ethics South East (reference number 2015/990), and the patients gave their written informed consent according to the Declaration of Helsinki.
: Not applicable.
: Dr. Uhlig reports personal fees from GrĂ¼nenthal and Novartis, outside the submitted work.Dres. Karoliussen, Sexton, and Borgen have nothing to disclose. Dr. Kvien reports grants and personal fees from AbbVie, MSD, UCB, Hospira/Pfizer, Eli-Lilly, grants from BMS, personal fees from Roche, Hikma, Orion, Sanofi, Celltrion, Sandoz, Biogen, Amgen, Egis, Ewopharma, and Mylan, outside the submitted work. Dr. Haavardsholm reports personal fees from Pfizer, UCB, Eli Lilly, Celgene, Janssen-Cilag, AbbVie, and Gilead outside the submitted work. Dr. Perez-Ruiz reports personal fees from Amgen, Biogen, and Galapagos, outside the submitted work, and personal fees from Algorithm, Alnylam, Astellas, Arthriti, Menarini, NMD, and Parexel, related to the topic of gout.Dr. Hammer reports personal fees from AbbVie, Lilly, and Novartis, outside the submitted work.